Study of Adebrelimab Plus Apatinib as Additional Treatment to Lower Recurrence Risk in Liver Cancer After Surgery

What this Trial Is About

Researchers are evaluating the combination of Adebrelimab and Apatinib as an additional treatment for people with hepatocellular carcinoma HCC who have a high risk of cancer returning after surgery. This Phase 2, single-center, open-label study focuses on assessing the safety and effectiveness of this treatment approach to improve survival and quality of life. The study includes a mid-term analysis at 6 months after enrolling 30 participants to review recurrence-free survival and overall survival rates. Participants will receive Adebrelimab at a dose of 1200 mg every 3 weeks combined with daily Apatinib 250 mg for the first 6 months or 8 treatment cycles. After this initial phase, Adebrelimab alone will be continued every 3 weeks for up to 2 years during the maintenance phase. The study follows a single-arm design without a placebo or comparison group. Throughout the study, participants will be monitored regularly for cancer recurrence and survival for up to 24 months, focusing on the recurrence-free survival rate as the primary outcome. Additional assessments include overall survival and time to recurrence over a 3-year period. Safety and liver function will be closely evaluated through clinical visits, laboratory tests, and imaging. Participants will be followed for up to three years to assess long-term outcomes and treatment effects.

Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection